Brain metastases represent an uncommon complication in malignant pleural mesothelioma. A 55-year-old male suffering from malignant mesothelioma and pretreated with intracavitary chemotherapy and radiotherapy was submitted to systemic chemotherapy including lomustine, carboplatin, vinorelbine, fluorouracil and folates after diagnosis of bilateral cerebral deposits. The patient had an impressive response to chemotherapy, with complete regression of related symptoms. This case report represents the first on response to chemotherapy of brain metastases from mesothelioma. It points out that chemotherapy should be further explored in this subset of patients.
AlbertsA.S., FalksonG., DoedhalsL.: Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.J. Clin. Oncol., 6: 527–535, 1988.
2.
ChahinianP., AntmanK., GoutsouM., CarsonJ.M., SuzukiY., ModeasC., HerndonJ.E.II, AisnerJ., EllisonR.R., LeoneL., VogelzangN.J., GreenM.R.: Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group.Br. J. Clin. Oncol., 8: 1559–1565, 1993.
3.
De CarliD., La VecchiaC.: Cancer mortality in Italy, 1990.Tumori, 76: 12–18, 1994.
4.
FalksonG., AlbertsA.S., FalksonH.C.: Malignant pleural mesothelioma treatment: the current state of the art.Cancer Treat. Rev., 15: 231–242, 1988.
5.
FuscoV., ArdizzoniA., MerloF., CinquegranaA., FaravelliB., De PalmaM.: Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.Anticancer Res., 13: 683–690, 1993.
6.
Krarup-HansenA., HansenH.H.: Chemotherapy in malignant mesothelioma: a review.Cancer Chemother. Pharmacol., 28: 319–330, 1991.
7.
LeghaS.S., MuggiaF.M.: Pleural mesothelioma: clinical features and therapeutic implications.Ann. Intern. Med., 87: 613–621, 1977.
8.
VogelzangN.J., GoutsonM., CorsonJ.M.: Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.Cancer Chemother. Pharmacol, 27: 239–242, 1990.
